EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic regulation of bladder cancer in the context of aging

Xuewei Liu, Guofeng Ding, Yifan Liu, Xiaoli Yan, Yan Zhao, Hailin Lv, Xiaojuan Xu

Frontiers in Pharmacology · 21.08.2025 · 16

DOI: 10.3389/fphar.2025.1617452 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.08.2025. Verfasst von Xuewei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer (BC) is a disease that predominantly affects older adults, with aging playing a critical role in its onset and progression. Age-associated phenomena, including immunosenescence and chronic inflammation, form a pro-tumor milieu, while genomic instability and epigenetic drift further increase cancer risk. The review highlights the dual role of DNA methylation in BC: global hypomethylation can activate transposable elements and oncogenes, whereas focal hypermethylation silences tumor-suppressor genes like CDKN2A, especially detrimental in older tissues that rely on these genes for senescence control. In parallel, frequent mutations in chromatin modifiers (e.g., KDM6A, KMT2D) and overexpression of histone-modifying enzymes (e.g., EZH2) alter the tumor epigenome to promote immune evasion and tumor aggressiveness. At the non-coding RNA level, dysregulated microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in BC contribute to aberrant proliferation, metastatic potential, and immune suppression, with aging-associated declines in miRNA processing further exacerbating these effects. Collectively, the accumulation of epigenetic alterations in older patients appears to facilitate both tumor progression and resistance to therapy. Looking forward, epigenetic biomarkers may improve early detection and risk stratification. Furthermore, “epigenetic therapies,” such as DNA methyltransferase inhibitors (DNMTi), EZH2 inhibitors (EZH2i), or histone deacetylases inhibitors (HDACi), hold promise to restore tumor-suppressor function and enhance immunogenicity, offering an attractive avenue for improving outcomes in older patients with BC.

Schlagwörter

Stichwörter der Autor:innen

DNA methylationagingbladder cancerepigeneticshistone modificationsimmunosenescencenon-coding RNAs

Autor:innen und Institutionen

  • Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
  • Stem Cell Research Center, Department of Pathology and Pathophysiology, School of Medicine, Tongji University, Shanghai, China.
  • Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Teaching Laboratory Center, School of Medicine, Tongji University, Shanghai, China.
  • Department of Nephrology, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China.

Zitieren

APA

Liu, X., Ding, G., Liu, Y., Yan, X., Zhao, Y., Lv, H., & Xu, X. (2025). Epigenetic regulation of bladder cancer in the context of aging. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1617452

Vancouver

Liu X, Ding G, Liu Y, Yan X, Zhao Y, Lv H, et al. Epigenetic regulation of bladder cancer in the context of aging. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1617452

BibTeX
@article{Liu2025,
  author = {Liu, Xuewei and Ding, Guofeng and Liu, Yifan and Yan, Xiaoli and Zhao, Yan and Lv, Hailin and Xu, Xiaojuan},
  title = {Epigenetic regulation of bladder cancer in the context of aging},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1617452}
}
Kostenlos starten →